Renata Varaljai
Essen, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
The role of KDM5B in creating synthetic vulnerabilities in combination with radiotherapy in melanoma cells.
Journal: Cell communication and signaling : CCS
Published: September 22, 2025
Raising the iron curtain: Lactate's secret role in oxidative stress defense.
Journal: Redox biology
Published: June 05, 2025
RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma.
Journal: Clinical and translational medicine
Published: May 16, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 28, 2023
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma.
Journal: The British journal of dermatology
Published: October 17, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Journal: Nature cancer
Published: August 14, 2023
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.
Journal: Clinical and translational medicine
Published: June 21, 2022
The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition.
Journal: International journal of molecular sciences
Published: February 23, 2022
BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment.
Journal: Cancer research
Published: April 16, 2021
Persister state-directed transitioning and vulnerability in melanoma.
Journal: Nature communications
Published: February 19, 2021
Last Updated: 09/26/2026